Nicotine - COVID / SARS / ARDS

From Safer nicotine wiki

Studies, Surveys, Papers, and Case Studies

  • Sometimes it's necessary to view the PDF version to access the full study.
  • This page is for referencing the possible benefits of Nicotine in the battle against COVID / SARS / ARDS.
  • If you'd prefer someone else to add a study to a topic, there is a subject section called "Suggested studies to add to this page". You may put the link in that section for one of the regular page editors to address.
  • PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.
    • Topic
    • Year (list new to old) Name of Study (In link format to the study)
    • Note here if animal study (leave blank if not)
    • Brief Summary
    • Link to PDF Version
    • Citation
    • Acknowledgements (funded by, helped by)
    • Keywords
    • Other


Suggested studies to add to this page

2021: Transdermal nicotine in non-smokers: a systematic review to design COVID-19 clinical trials

2021: Impact of Tobacco Smoking on the risk of COVID-19.A large scale retrospective cohort study

2020: Does Nicotine Prevent Cytokine Storms in COVID-19?

2020: Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm

Threads about COVID on Twitter by @phil_w888

So far all existing data show smokers are underrepresented in Covid19 hospitalization data


The results of preprints & peer-reviewed studies describing the relationship between smoking and SARS-CoV-2/COVID-19 are reported in this thread


A compilation of preprints, peer-reviewed studies, and datasets documenting SARS-CoV-2/Covid-19 patients' smoking status - only the ones with at least 1000 patients.

  • Thread on twitter


Studies of SARS-CoV-2/Covid-19 patients in which vaping is mentioned

  • Thread on twitter


Nicotine Replacement Therapy (NRT)

2020: Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France

From February 15, 2020 to June 7, 2020, hospitalization with Covid-19 occurred in 647 patients (151 patients in the nicotine-replacement therapy group and 496 patients in the unexposed group). Results In the first analysis, 297,070 individuals without major smoking-related diseases exposed to nicotine-replacement therapy were matched with 558,228 unexposed individuals without major smoking-related diseases. In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19. (13 vs. 73 patients).


Smoking

2020: How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?

COVID-19 positive patients who smoke are more often asymptomatic or exhibit less severe respiratory symptoms than non-smokers. The macrophages, which are directly infected by the SARS-CoV-2 virus, may drive the cytokine storm in the lings. Stimulation of macrophage ACh receptors by nicotine inhibits pro-inflammatory cytokines production and inflammatory response. The nicotine use may lessen or eliminate ARDS in the smoking COVID -19 patients.


2020: Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases

COVID-19 patients were disproportionately older, males and with increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers.


Smokeless Tobacco

Vapor Technology

More Information

  • Click on the category link below for more studies by topic on Nicotine.
Cookies help us deliver our services. By using our services, you agree to our use of cookies.